These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32363973)

  • 1. The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout.
    Huang YY; Ye Z; Gu SW; Jiang ZY; Zhao L
    J Int Med Res; 2020 May; 48(5):300060520902950. PubMed ID: 32363973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
    Wang S
    Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
    Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
    Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.
    Hosoya T; Furuno K; Kanda S
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):71-79. PubMed ID: 31970593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
    Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
    Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
    Lertnawapan R; Jatuworapruk K
    Clin Rheumatol; 2021 Jan; 40(1):255-262. PubMed ID: 32607660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout.
    Frampton JE
    Drugs; 2015 Mar; 75(4):427-38. PubMed ID: 25724536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Febuxostat.
    Hair PI; McCormack PL; Keating GM
    Drugs; 2008; 68(13):1865-74. PubMed ID: 18729537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
    Zhou Q; Su J; Zhou T; Tian J; Chen X; Zhu J
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):163-168. PubMed ID: 27936522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of febuxostat on serum urate level in Japanese hyperuricemia patients.
    Yamamoto T; Hidaka Y; Inaba M; Ishimura E; Ooyama H; Kakuda H; Moriwaki Y; Higami K; Ohtawara A; Hosoya T; Nishikawa H; Taniguchi A; Ueda T; Yamauchi T; Fujimori S; Mineo I; Yamanaka H
    Mod Rheumatol; 2015 Sep; 25(5):779-83. PubMed ID: 25671406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Febuxostat for the treatment of hyperuricaemia in gout.
    Robinson PC; Dalbeth N
    Expert Opin Pharmacother; 2018 Aug; 19(11):1289-1299. PubMed ID: 30024787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
    Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
    Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.
    Dalbeth N; Saag KG; Palmer WE; Choi HK; Hunt B; MacDonald PA; Thienel U; Gunawardhana L
    Arthritis Rheumatol; 2017 Dec; 69(12):2386-2395. PubMed ID: 28975718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.